ARKG241206C27000
- 0.15
- -0.20-57.14%
ARK Genomic Revolution ETF Newsroom
Stocks With Improving and Deteriorating 'TechniGrade' by Piper Sandler
Recursion Announces First Patient Dosed In Phase 1/2 Clinical Study Of REC-1245, A RBM39 Degrader For Biomarker-Enriched Solid Tumors And Lymphoma
Follow Nvidia's Lead in Investing in Small-Cap AI Stocks
Looking Into Natera's Recent Short Interest
XPeng, NovoCure, Merus, Gap And Other Big Stocks Moving Higher On Monday
Cathie Wood Sees Tesla As 'Largest AI Project On Earth' — Here's Why She's Not Worried About Tech Investments
(RXRX) - Analyzing Recursion Pharmaceuticals's Short Interest
Jim Cramer: Reddit Is 'Fabulous,' Dow Is A 'Tough' One
Cathie Wood Sees $400B Opportunity In Biologics — How Have Her Bets Fared?
Natera Issues Statement On Guardant Health Litigation; Says "A Jury Issued A Decision In Guardant's Favor. We Disagree With This Decision And Will Ask The Court To Overturn It"
JPMorgan Updates Its U.S. Analyst Focus List – Adds TPR, ALRM, REG
Goldman's Hedge Fund VIP List: AMZN, VST, CRM, BABA, and More
Recursion Pharmaceuticals Analyst Ratings
Trump Media Saw the Largest Increase in Short Interest in October
Barclays Maintains Overweight on Twist Bioscience, Lowers Price Target to $52
JPMorgan's 'Analyst Focus List' – Growth, Income, Value, Short Ideas
Baird Maintains Outperform on Twist Bioscience, Raises Price Target to $48
Twist Bioscience Analyst Ratings
12 Health Care Stocks Moving In Monday's Pre-Market Session
Analyst Expectations For Natera's Future